We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. 
We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers.

We have four proprietary AI prediction models: PIONEER, ObsERV, EDEN and RAVEN.

National Institutes of Health

Lincoln Park Capital Fund

Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

COM:EVAXION-BIOTECH

Evaxion Biotech A/S

Last Close

1.39

22/11 21:00

Market Cap

16.59M

Beta: -

Volume Today

13.33K

Avg: -

Filings Not Available